You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 156 No. 13, 8 JULY 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  SPECIAL ARTICLE
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Physicians' Desk Reference

Problems and Possible Improvements

Jay S. Cohen, MD; Paul A. Insel, MD

Arch Intern Med. 1996;156(13):1375-1380.


Abstract

The Physicians' Desk Reference (PDR) is a widely used source of drug information by American physicians and patients, but as we shall discuss, it suffers from numerous shortcomings.1 The PDR is a collection of written and pictorial information that is provided and paid for by pharmaceutical manufacturers. The written material for a given drug is a compilation of data and recommendations that are identical to those in the drug's package insert. The wording and directives that are included in these package inserts (and thus in the PDR) represent information that the pharmaceutical companies are permitted to present following discussion and approval by the Food and Drug Administration (FDA), Rockville, Md. The PDR is thus a negotiated effort of commercial enterprises and governmental regulators.



Author Affiliations

From the Departments of Psychiatry (Dr Cohen) and Pharmacology and Medicine (Dr Insel), University of California, San Diego, School of Medicine, La Jolla.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Pharmaceutical Manufacturer Sponsorship and Drug Information
Ethan M. Basch, Mark F. Bonfiglio, and Jay S. Cohen
Arch Intern Med. 2001;161(21):2625-2626.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Why Aren't Lower, Effective, OTC Doses Available Earlier by Prescription?
Cohen
The Annals of Pharmacotherapy 2003;37:136-142.
ABSTRACT | FULL TEXT  

Timing of New Black Box Warnings and Withdrawals for Prescription Medications
Lasser et al.
JAMA 2002;287:2215-2220.
ABSTRACT | FULL TEXT  

Pharmaceutical Manufacturer Sponsorship and Drug Information
Basch et al.
Arch Intern Med 2001;161:2625-2626.
FULL TEXT  

Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events
Cohen
Arch Intern Med 2001;161:957-964.
ABSTRACT | FULL TEXT  

Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians' Desk Reference
Cohen
Arch Intern Med 2001;161:880-885.
ABSTRACT | FULL TEXT  

The PDR: Another View
Jones
Arch Intern Med 1997;157:576-576.
ABSTRACT  

The American Hospital Formulary Service Information Books Beat the PDR
Hooper
Arch Intern Med 1997;157:575-576.
ABSTRACT  

The PDR Is Food and Drug Administation-Approved Labeling
Oddis
Arch Intern Med 1997;157:576-579.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.